These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 26656977)

  • 21. Therapeutic Cancer Vaccines.
    Ye Z; Li Z; Jin H; Qian Q
    Adv Exp Med Biol; 2016; 909():139-67. PubMed ID: 27240458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune checkpoint modulation: rational design of combination strategies.
    Zamarin D; Postow MA
    Pharmacol Ther; 2015 Jun; 150():23-32. PubMed ID: 25583297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The fourth modality: immunotherapy for head and neck cancer hits pay dirt.
    Bell RB
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Jun; 121(6):575-7. PubMed ID: 27181440
    [No Abstract]   [Full Text] [Related]  

  • 24. Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors.
    Aspeslagh S; Marabelle A; Soria JC; Armand JP
    Chin Clin Oncol; 2015 Dec; 4(4):48. PubMed ID: 26730760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale for combining immunotherapy with chemotherapy.
    Dalgleish AG
    Immunotherapy; 2015; 7(3):309-16. PubMed ID: 25804482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control.
    Schoenhals JE; Seyedin SN; Tang C; Cortez MA; Niknam S; Tsouko E; Chang JY; Hahn SM; Welsh JW
    Cancer J; 2016; 22(2):130-7. PubMed ID: 27111909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Various ways to improve whole cancer cell vaccines.
    Cicchelero L; de Rooster H; Sanders NN
    Expert Rev Vaccines; 2014 Jun; 13(6):721-35. PubMed ID: 24758597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing equals when evaluating immunotherapy with different doses and fractions of radiation therapy.
    Gough MJ; Crittenden MR; Young KH
    Immunotherapy; 2015; 7(8):847-9. PubMed ID: 26268988
    [No Abstract]   [Full Text] [Related]  

  • 29. Contemporary immunotherapy of solid tumors: from tumor-associated antigens to combination treatments.
    Spagnoli GC; Ebrahimi M; Iezzi G; Mengus C; Zajac P
    Curr Opin Drug Discov Devel; 2010 Mar; 13(2):184-92. PubMed ID: 20205052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combining radiotherapy with immunotherapy: the past, the present and the future.
    Van Limbergen EJ; De Ruysscher DK; Olivo Pimentel V; Marcus D; Berbee M; Hoeben A; Rekers N; Theys J; Yaromina A; Dubois LJ; Lambin P
    Br J Radiol; 2017 Aug; 90(1076):20170157. PubMed ID: 28541096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination strategies to maximize the benefits of cancer immunotherapy.
    Zhu S; Zhang T; Zheng L; Liu H; Song W; Liu D; Li Z; Pan CX
    J Hematol Oncol; 2021 Sep; 14(1):156. PubMed ID: 34579759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining radiotherapy and immunotherapy: a revived partnership.
    Demaria S; Bhardwaj N; McBride WH; Formenti SC
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):655-66. PubMed ID: 16199306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune targets in the tumor microenvironment treated by radiotherapy.
    Ozpiskin OM; Zhang L; Li JJ
    Theranostics; 2019; 9(5):1215-1231. PubMed ID: 30867826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Injecting Hope--A Review of Breast Cancer Vaccines.
    Mittendorf EA; Peoples GE
    Oncology (Williston Park); 2016 May; 30(5):475-81, 485. PubMed ID: 27188680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.
    Ceppi F; Beck-Popovic M; Bourquin JP; Renella R
    Eur J Pediatr; 2017 Sep; 176(9):1163-1172. PubMed ID: 28803259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immuno-oncology combinations: a review of clinical experience and future prospects.
    Antonia SJ; Larkin J; Ascierto PA
    Clin Cancer Res; 2014 Dec; 20(24):6258-68. PubMed ID: 25341541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer vaccines. Any future?
    Myc LA; Gamian A; Myc A
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
    Terranova-Barberio M; Thomas S; Munster PN
    Immunotherapy; 2016 Jun; 8(6):705-19. PubMed ID: 27197539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccines versus immunotherapy: overview of approaches in deciding between options.
    Dalgleish AG
    Hum Vaccin Immunother; 2014; 10(11):3369-74. PubMed ID: 25625932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined Immune Checkpoint Blockade.
    Drake CG
    Semin Oncol; 2015 Aug; 42(4):656-62. PubMed ID: 26320068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.